The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Feb. 27, 4:02 PM

Slide #18. PDS Biotechnology Corporation Secondary Offering

Company: PDS Biotechnology Corporation (NASDAQ:PDSB)
Date announced: 2/11/2020
Shares Offered: 9,230,770
Date of Pricing: 2/11/2020
Price Per Share: $1.30
Secondary Offering Details: PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on PDS Biotechnology's proprietary Versamune T-cell activating technology, today announced the pricing of an underwritten public offering consisting of 9,230,770 shares of common stock at a price to the public of $1.30 per share. The gross proceeds to PDS Biotechnology from this offering are expected to be approximately $12,000,000, before deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on Friday, February 14, 2020, subject to customary closing conditions.

PDS Biotechnology is a clinical stage immuno-oncology company with a pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. All of Co.'s products are based on the proprietary Versamune® platform technology, which activates and directs the human immune system against cancer cells.
Open the PDSB Page at The Online Investor »

Company Name: 
PDS Biotechnology Corp
Drugs & Pharmaceuticals
Number of ETFs Holding PDSB: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the PDSB Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
86th percentile
(ranked higher than approx. 86% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.